Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?

Abstract

Next generation sequencing (NGS) coupled with sophisticated bioinformatics tools yields an unprecedented amount of information regarding tumor genetics, with the potential to reveal insights into tumor behavior. NGS and other multiplex genomic assays are rapidly spilling from the laboratory into the clinic through numerous commercial and academic entities. This raises the important question as to whether we are ready to use these data in clinical decision-making. While genetic lesions are clearly targeted by a new generation of biological cancer therapies, and certain regulatory approvals are actually coupled to single gene assays, we still do not know if the vast information on other genomic alterations is worth the added cost, or even worse, the inappropriate and unproven assignment of patients to treatment with an unapproved drug carrying potentially serious side effects. On the other hand, the trend toward a precision medicine pathway is clearly accelerating, and clinical trials validating pathway-driven personalized cancer therapeutics will be necessary in both the community and academic settings. Lower cost and wider availability of NGS now raises a debate over the merit of routine tumor genome-wide analysis.

Extra-virgin olive oil ameliorates cognition and neuropathology of the 3xTg mice: role of autophagy

“…Thus, the results of several cross‐sectional investigations have been mainly consistent showing positive outcomes. Among the key elements of the Mediterranean diet, an important role has been attributed to daily intake of fresh fruit and vegetable, cereals, beans, and legumes and the usage of EVOO as a primary source of fat 22. In particular, average daily consumption of 30–50 mL per day of EVOO has been suggested as the most important and integral component of the diet23, 24 resulting in the common idea that EVOO plays a major role in the health benefit of this diet.…”

Germline Analysis from Tumor–Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings

“…Whether next generation sequencing should be applied on a routine basis for tumor mutation profiling remains to be determined(42) though it is a major focus of precision medicine efforts. We demonstrate here that utilizing an incidental/secondary variant analysis approach for germline sequence data in unselected patients undergoing somatic sequencing may provide a small but important benefit with regard to the detection of clinically relevant, highly penetrant variants in hereditary cancer predisposition genes.…”

Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology

“…In the absence of “actionable” oncogenic mutations, these may have some relevance in the prospective enrollment of patients in pre-clinical or clinical trials for targeted therapy. 96,97 …”